Dyadic International, Inc. (OTCBB:DYAD), a biotechnology
company, announced today that it has appointed Harry Z. Rosengart to
its Board of Directors. The appointment increases the number of
Directors to five, including four independent Directors. Mr. Rosengart
has extensive experience in the biotechnology sector in banking and
consulting capacities and as the founder of several privately-held
companies.
He is currently the President and CEO of HK & Associates, an investment and consulting firm which provides advice to small and medium-sized life sciences companies and life-science investment firms. Previously, he founded several privately held companies, including LigoChem, Inc., a DNA\RNA and macromolecule bioseparations company founded in 1995; SunPharm Corporation, a polyamine based anti-cancer drug development-stage company founded in 1991 and Syncom Pharmaceuticals, Inc., a contract sales force organization founded in 1991. Between 1981 and 1990, Mr. Rosengart spent almost ten years as a banker and investment banker with the Chase Manhattan Bank, NA, focusing on the pharmaceutical and chemical industries. Prior to joining Chase Manhattan Bank, he spent over ten years with several pharmaceutical and chemical multinational companies in various managerial positions. Mr. Rosengart holds a B.S. in Chemical Engineering and an M.B.A. from Rutgers University.
"The appointment of Harry further enhances our experienced Board of Directors," said Mark Emalfarb, Dyadic's President and CEO. "He has been involved in many facets of the biotechnology industry, understanding the challenges of building a business, successfully raising capital for his companies and others, and providing advice to third parties. With the upcoming completion of the C1 sequencing project, we anticipate generating substantial product leads for our Enzyme Business and our collaborators. Since we have already demonstrated the ability to produce and sell large volumes of low cost enzymes from the genes originating from the C1 genome, we believe that we have a reliable method for developing commercial production processes from the genes.
"With so many uses for proteins and enzymes, one of our biggest challenges is to sort through the many opportunities available to Dyadic," continued Mr. Emalfarb. "We are fortunate to be in a position to choose from several viable alternatives and believe that the guidance from our experienced Board of Directors and Scientific Advisory Board members will assist the Dyadic management team in this process."
About Dyadic:
Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products.
Cautionary Statement for Forward-Looking Statements
Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. For a discussion of the factors that could cause actual results to vary from these forward-looking statements, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, which was filed with the SEC on April 15, 2005. We expressly disclaim any intent or obligation to update any forward-looking statements.
He is currently the President and CEO of HK & Associates, an investment and consulting firm which provides advice to small and medium-sized life sciences companies and life-science investment firms. Previously, he founded several privately held companies, including LigoChem, Inc., a DNA\RNA and macromolecule bioseparations company founded in 1995; SunPharm Corporation, a polyamine based anti-cancer drug development-stage company founded in 1991 and Syncom Pharmaceuticals, Inc., a contract sales force organization founded in 1991. Between 1981 and 1990, Mr. Rosengart spent almost ten years as a banker and investment banker with the Chase Manhattan Bank, NA, focusing on the pharmaceutical and chemical industries. Prior to joining Chase Manhattan Bank, he spent over ten years with several pharmaceutical and chemical multinational companies in various managerial positions. Mr. Rosengart holds a B.S. in Chemical Engineering and an M.B.A. from Rutgers University.
"The appointment of Harry further enhances our experienced Board of Directors," said Mark Emalfarb, Dyadic's President and CEO. "He has been involved in many facets of the biotechnology industry, understanding the challenges of building a business, successfully raising capital for his companies and others, and providing advice to third parties. With the upcoming completion of the C1 sequencing project, we anticipate generating substantial product leads for our Enzyme Business and our collaborators. Since we have already demonstrated the ability to produce and sell large volumes of low cost enzymes from the genes originating from the C1 genome, we believe that we have a reliable method for developing commercial production processes from the genes.
"With so many uses for proteins and enzymes, one of our biggest challenges is to sort through the many opportunities available to Dyadic," continued Mr. Emalfarb. "We are fortunate to be in a position to choose from several viable alternatives and believe that the guidance from our experienced Board of Directors and Scientific Advisory Board members will assist the Dyadic management team in this process."
About Dyadic:
Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products.
Cautionary Statement for Forward-Looking Statements
Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. For a discussion of the factors that could cause actual results to vary from these forward-looking statements, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, which was filed with the SEC on April 15, 2005. We expressly disclaim any intent or obligation to update any forward-looking statements.
© 2005 Business Wire
